Supplementation of Thyroid Hormone for TSH Control in Patients With Chronic Kidney Disease Without TRR. (TSHrenal)
Chronic Kidney Diseases, Subclinical Hypothyroidism
About this trial
This is an interventional treatment trial for Chronic Kidney Diseases
Eligibility Criteria
Inclusion Criteria:
• Patients older than 18 years
- Patients with chronic kidney disease G2-G5 without renal replacement therapy) who attend a renal health clinic.
- Presence of proteinuria in a test strip, 24 hours urine collection (greater than 150mg / dl in 24hrs urine)
- TSH <9.9uiml / L and TSH> 2.4 0uiml / L
- Take an IECA or ARA-2
- Patients with weight> 50 kg and <80kg
- Accept informed consent
Exclusion Criteria:
Chronic dialysis (peritoneal dialysis or hemodialysis)
- Primary hypothyroidism or preexisting thyroid disease
- Use of levothyroxine.
- TSH> 10uiml / L and TSH <2.5 0uiml / L
- Positive thyroid antibodies
- Ischemic heart disease in less than 6 months
- Cardiac arrhythmia
- Use Medications (Levothyroxine synthesis, see Table 2)
- Anxiety disorder
- Pregnancy
- Do not accept consent
- Patients weighing <50 kg and> 80kg
Sites / Locations
- Kidney health clinic, Civil Hospital of Guadalajara
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Group with levothyroxine
Group Placebo
Patients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. That meet the inclusion criteria. Levothyroxine 25 mcg (1/4 tablet of 100mcg) was administered in fasting the first month, the doctor evaluated with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 uim / L the second month increase to a dose of 50 mcg (1/2 tablet of 100mcg fasting, or similarly if the patient had a TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5u / L ) to complete three months of intervention.
atients with Chronic Kidney Disease G2-G5 with proteinuria without renal replacement therapy, who comes to the clinic of renal health clinic of Fray Antonio Alcalde civil hospital. that meet the inclusion criteria. Placebo (1/4 tablet) was administered in fasting the first month, the doctor assessed with monthly control of TSH levels (if the TSH level was not in the range of TSH 1-2.5 UM / L the second month increase at a dose (1/2 tablet fasting, or similarly if the patient had TSH <1 u / L was suspended in medication and it was valued restart the next month the medication if TSH> 2.5 / month) to complete three months of intervention.